Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global Vaccine Market 2018-2022 - Rising Prevelance of Diseases Driving the Projected $49.2 Billion Market - Research and Markets

Research and Markets
Posted on: 09 Jan 18

The "Vaccine Market by Technology (Live, Conjugate, Toxoid, Recombinant), Disease (Influenza, DTaP, HPV, Hepatitis, Rotavirus, TT, Polio, MMR, Varicella, Dengue, TB, Rabies), Route (IM, SC, ID, Oral), End User (Pediatric, Adult) & Type - Forecast to 2022" report has been added to Research and Markets' offering.

The vaccines market is expected to reach USD 49.27 Billion by 2022 from USD 34.30 Billion in 2017, at a CAGR of 7.5%.

Factors such as rising prevalence of diseases, increasing government and nongovernment funding for vaccine development, and increasing investments by companies are driving the vaccine market.

In 2017, North America is expected to dominate the market, followed by Europe. The high growth of the North American market is attributed to the factors such as increasing investments by government organizations and companies to promote immunization as well as develop new vaccines.

While North America is expected to dominate the market in 2017, Asia is expected to register the highest CAGR during the forecast period. The high growth in this market is attributed to increasing investments by companies in the emerging countries of the Asian region such as India and China and rising disposable income.

While the vaccines market presents significant growth opportunities, market growth may be hindered due to the high cost of vaccine development and product recalls.

The vaccine market is highly competitive with several big and small players. Prominent players in the market include Astellas Pharma Inc. (Japan), CSL Limited (Australia), Emergent BioSolutions, Inc. (U.S.), GlaxoSmithKline, plc (U.K.), Johnson & Johnson (U.S.), MedImmune, LLC (U.S.), Merck & Co., Inc. (U.S.), Pfizer, Inc. (U.S.), Sanofi Pasteur SA (France), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo (Japan), Protein Sciences Corporation (U.S.), and Panacea Biotec (India).

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Industry Insights

7 Global Vaccines Market, By Technology

8 Global Vaccines Market, By Type

9 Global Vaccines Market, By Disease Indication

10 Global Vaccines Market, By Route of Administration

11 Global Vaccines Market, By End-User

12 Global Vaccines Market, By Region

13 Competitive Landscape

14 Company Profiles

  • Astellas Pharma, Inc.
  • Bavarian Nordic
  • CSL Limited
  • Daiichi Sankyo Company, Limited
  • Emergent Biosolutions, Inc.
  • Glaxosmithkline Plc.
  • Johnson & Johnson
  • Medimmune, Llc (A Subsidiary of Astrazeneca)
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Panacea Biotec
  • Pfizer, Inc.
  • Protein Sciences Corporation
  • Sanofi Pasteur Sa
  • Serum Institute of India

For more information about this report visit

View source version on

Business Wire

Last updated on: 09/01/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.